830346-49-1 Usage
Description
Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester, also known as Elagolix Methoxy-d3 Sodium Salt (E501024), is a labeled analogue of Elagolix (E50108). It is a novel uracil phenylethylamine that acts as a potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonist.
Uses
Used in Pharmaceutical Industry:
Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester is used as an intermediate in the synthesis of Elagolix Methoxy-d3 Sodium Salt (E501024). Carbamic acid, N-[(1R)-2-[5-bromo-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester is a potent hGnRH-R antagonist, which has potential applications in the development of treatments for various hormonal disorders and conditions related to the gonadotropin-releasing hormone receptor.
Check Digit Verification of cas no
The CAS Registry Mumber 830346-49-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,3,0,3,4 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 830346-49:
(8*8)+(7*3)+(6*0)+(5*3)+(4*4)+(3*6)+(2*4)+(1*9)=151
151 % 10 = 1
So 830346-49-1 is a valid CAS Registry Number.
InChI:InChI=1/C26H26BrF4N3O4/c1-15-21(27)22(35)34(14-20(16-9-6-5-7-10-16)32-23(36)38-25(2,3)4)24(37)33(15)13-17-18(26(29,30)31)11-8-12-19(17)28/h5-12,20H,13-14H2,1-4H3,(H,32,36)/t20-/m0/s1
830346-49-1Relevant articles and documents
Oxagolix intermediate, and preparation method and application thereof
-
, (2021/02/10)
The invention provides a preparation method of a novel oxagolix important intermediate compound 1, and also provides two novel intermediate compounds 5 and 6. By starting from the novel intermediate compound 5, the five-step synthesis in the prior art is
AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
, (2021/07/02)
The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.
PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM AND INTERMEDIATES THEREOF
-
Page/Page column 25, (2020/10/17)
The present invention relates to compounds of Formula A, isomers, polymorphs and process of preparation thereof, wherein, S is a pharmaceutically acceptable salt, R is selected from hydrogen or C1-C3 alkyl group substituted with Rsu